The role of vascular cell senescence in atherosclerosis: Antisenescence as a novel therapeutic strategy for vascular aging

Current Vascular Pharmacology

Volumn 2, Issue 2, 2004, Pages 141-148

  Minamino, Tohru ^a   Miyauchi, Hideyuki ^a   Yoshida, Toshihiko ^a   Tateno, Kaoru ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aging; Atherosclerosis; Senescence; Telomere

Indexed keywords

ANTIOXIDANT; CYCLIN DEPENDENT KINASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN INHIBITOR; PROTEIN P21; PROTEIN P53; RAS PROTEIN; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

AGING; ATHEROGENESIS; ATHEROSCLEROSIS; CELL ACTIVITY; CELL AGING; CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME SIZE; DISEASE ASSOCIATION; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE ACTIVATION; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STIMULUS RESPONSE; TELOMERE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

BLOOD VESSELS; CELL AGING; CELL CYCLE; CELLS, CULTURED; CORONARY ARTERIOSCLEROSIS; HUMANS; TELOMERE;

EID: 3042698408     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570161043476393     Document Type: Review

References (97)

1. Faragher RG, Kipling D. How might replicative senescence contribute to human ageing? Bioessays 1998; 20: 985-91.
2. Hayflick L. Current theories of biological aging. Fed Proc 1975; 34: 9-13.
3. Schneider EL, Mitsui Y. The relationship between in vitro cellular aging and in vivo human age. Proc Natl Acad Sci USA 1976; 73: 3584-8.
4. Rohme D. Evidence for a relationship between longevity of mammalian species and life spans of normal fibroblasts in vitro and erythrocytes in vivo. Proc Natl Acad Sci USA 1981; 78: 5009-13.
5. Thompson KV, Holliday R. Genetic effects on the longevity of cultured human fibroblasts. II. DNA repair deficient syndromes. Gerontology 1983; 29: 83-8.
6. Burrig KF. The endothelium of advanced arteriosclerotic plaques in humans. Arterioscler Thromb 1991; 11: 1678-89.
7. Ross R, Wight TN, Strandness E, Thiele B. Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol 1984; 114: 79-93.
8. Kumazaki T, Kobayashi M, Mitsui Y. Enhanced expression of fibronectin during in vivo cellular aging of human vascular endothelial cells and skin fibroblasts. Exp Cell Res 1993; 205: 396-402.
9. Bennett MR, Macdonald K, Chan SW, Boyle JJ, Weissberg PL. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res 1998; 82: 704-12.
10. Liao S, Curci JA, Kelley BJ, Sicard GA, Thompson RW. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res 2000; 92: 85-95.
11. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-7.
12. van der Loo B, Fenton MJ, Erusalimsky JD. Cytochemical detection of a senescence-associated beta-galactosidase in endothelial and smooth muscle cells from human and rabbit blood vessels. Exp Cell Res 1998; 241: 309-15.
13. Fenton M, Barker S, Kurz DJ, Erusalimsky JD. Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol 2001; 21: 220-6.
14. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541-4.
15. Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H, et al. Ras-induced vascular smooth muscle cell senescence in human atherosclerosis. Circulation In press.
16. Marin J. Age-related changes in vascular responses: a review. Mech Ageing Dev 1995; 79: 71-114.
17. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99: 111-20.
18. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
19. Cooper LT, Cooke JP, Dzau VJ. The vasculopathy of aging. J Gerontol 1994; 49: B191-6.
20. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
21. Sato I, Morita I, Kaji K, Ikeda M, Nagao M, Murota S. Reduction of nitric oxide producing activity associated with in vitro aging in cultured human umbilical vein endothelial cell. Biochem Biophys Res Commun 1993; 195: 1070-6.
22. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Circ Res 2001; 89: 793-8.
23. Hoffmann J, Haendeler J, Icier A, Rossig L, Vasa M, Zeiher AM, et al. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res 2001; 89: 709-15.
24. Nakajima M, Hashimoto M, Wang F, Yamanaga K, Nakamura N, Uchida T, et al. Aging decreases the production of PG12 in rat aortic endothelial cells. Exp Gerontol 1997; 32: 685-93.
25. Comi P, Chiaramonte R, Maier JA. Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. Exp Cell Res 1995; 219: 304-8.
26. Maier JA, Statuto M, Ragnotti G. Senescence stimulates U937-endothelial cell interactions. Exp Cell Res 1993; 208: 270-4.
27. Rivard A, Berthou-Soulie L, Principe N, Kearney M, Curry C, Branellec D, et al. Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J Biol Chem 2000; 275: 29643-7.
28. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem 1999; 274: 26141-8.
29. Crass MF 3rd, Borst SE, Scarpace PJ. Beta-adrenergic responsiveness in cultured aorta smooth muscle cells. Effects of subculture and aging. Biochem Pharmacol 1992; 43: 1811-5.
30. Robert L, Robert AM, Jacotot B. Elastin-elastase-atherosclerosis revisited. Atherosclerosis 1998; 140: 281-95.
31. Campisi J, Kim SH, Lim CS, Rubio M. Cellular senescence, cancer and aging: the telomere connection. Exp Gerontol 2001; 36: 1619-37.
32. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol 2001; 13: 748-53.
33. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
34. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92: 11190-4.
35. Minamino T, Mitsialis SA, Kourembanas S. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Mol Cell Biol 2001; 21: 3336-42.
36. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-73.
37. Baumann P, Cech TR. Potl, the putative telomere end-binding protein in fission yeast and humans. Science 2001; 292: 1171-5.
38. Hsu HL, Gilley D, Blackburn EH, Chen DJ. Ku is associated with the telomere in mammals. Proc Natl Acad Sci USA 1999; 96: 12454-8.
39. Broccoli D, Smogorzewska A, Chong L, de Lange T. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet 1997; 17: 231-5.
40. Espejel S, Franco S, Rodriguez-Perales S, Bouffler SD, Cigudosa JC, Blasco MA. Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically short telomeres. EMBO J 2002; 21: 2207-19.
41. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.
42. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-13.
43. Smogorzewska A, de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 2002; 21: 4338-48.
44. Baur JA, Zou Y, Shay JW, Wright WE. Telomere position effect in human cells. Science 2001; 292: 2075-7.
45. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
46. Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 2000; 20: 273-85.
47. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12: 3008-19.
48. Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22: 3389-403.
49. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12: 2984-91.
50. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998; 395: 125-6.
51. Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM, et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet 2000; 26: 291-9.
52. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14: 2015-27.
53. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-10.
54. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-38.
55. Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC. Two posttranscriptional pathways that regulate p21(Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res 1999; 247: 168-75.
56. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001; 409: 1067-70.
57. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998; 8: 351-4.
58. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
59. Xu D, Neville R, Finkel T. Homocysteine accelerates endothelial cell senescence. FEBS Lett 2000; 470: 20-4.
60. Breitschopf K, Zeiher AM, Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett 2001; 493: 21-5.
61. Furumoto K, Inoue E, Nagao N, Hiyama E, Miwa N. Age-dependent telomere shortening is slowed down by enrichment of intracellular vitamin C via suppression of oxidative stress. Life Sci 1998; 63: 935-48.
62. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 2000; 87: 540-2.
63. Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M. et al. Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3. J Biol Chem 2001; 276: 36194-9.
64. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999; 274: 7936-40.
65. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, Lee SW, et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 2002; 21: 2180-8.
66. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321-5.
67. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
68. Lee HW, Blasco MA, Gottlieb GJ, Horner JW 2nd, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392: 569-74.
69. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-12.
70. Franco S, Segura I, Riese HH, Blasco MA. Decreased B16F10 melanoma growth and impaired vascularization in telomerase-deficient mice with critically short telomeres. Cancer Res 2002; 62: 552-9.
71. Aviv H, Khan MY, Skurnick J, Okuda K, Kimura M, Gardner J, et al. Age dependent aneuploidy and telomere length of the human vascular endothelium. Atherosclerosis 2001; 159: 281-7.
72. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001; 37: 381-5.
73. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet 2001; 358: 472-3.
74. Okuda K, Khan MY, Skurnick J, Kimura M, Aviv H, Aviv A. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 2000; 152: 391-8.
75. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
76. Minamino T, Kourembanas S. Mechanisms of telomerase induction during vascular smooth muscle cell proliferation. Circ Res 2001; 89: 237-43.
77. Hsiao R, Sharma HW, Ramakrishnan S, Keith E, Narayanan R. Telomerase activity in normal human endothelial cells. Anticancer Res 1997; 17: 827-32.
78. Yang J, Nagavarapu U, Relloma K, Sjaastad MD, Moss WC, Passaniti A, et al. Telomerized human microvasculature is functional in vivo. Nat Biotechnol 2001; 19: 219-24.
79. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
80. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-8.
81. Vasa M, Fichtlscherer S, Icier A, Adler K, Urbich C, Martin H. et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
82. Murasawa S, Llevadot J, Silver M, Isner JM, Losordo DW, Asahara T. Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 2002; 106: 1133-9.
83. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
84. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
85. Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 2002; 37: 1175-87.
86. Ihling C, Menzel G, Wellens E, Monting JS, Schaefer HE, Zeiher AM. Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arterioscler Thromb Vasc Biol 1997; 17: 2218-24.
87. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 1999; 5: 335-9.
88. van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ, et al. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 2001; 88: 780-6.
89. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, et al. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation 2002; 105: 2064-70.
90. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev 2002; 12: 80-5.
91. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J 1999; 13: 2091-104.
92. Peeper DS, Shvarts A, Brummelkamp T, Douma S, Koh EY, Daley GQ, et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol 2002; 4: 148-53.
93. Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA 1995; 92: 4337-41.
94. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 1994; 91: 4130-4.
95. Wojcicki J, Rozewicka L, Barcew-Wiszniewska B, Samochowiec L, Juzwiak S, Kadlubowska D, et al. Effect of selenium and vitamin E on the development of experimental atherosclerosis in rabbits. Atherosclerosis 1991; 87: 9-16.
96. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105: 2107-11.
97. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 2017-23.